---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX19-147-007"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX19-147-007. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 23 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence/vx19-147-007"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: VX19-147-007

<a id="heading-3.1.6"></a>

## 3.1.6 VX19-147-007

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Purpose stated in the registry record

> “The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.1-2"></a>

#### Aim stated in the congress abstract

> “We evaluated the pharmacokinetics (PK) of IXP in participants with renal or hepatic impairment compared to the PK in matched healthy participants in 2 separate studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2023-06-12” |
| Primary completion (actual) | “2024-06-12” |
| Study completion (actual) | “2024-06-12” |
| First posted | “2023-05-18” |
| Last update posted | “2024-07-12” |
| Other study ID numbers | “VX19-147-007” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.2-2"></a>

#### Study locations in the registry record

> “This study has 2 locations”
> “Ocala, Florida, United States, 34471”
> “Tampa, Florida, United States, 33603”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.2-3"></a>

#### Presentation at the NKF 2026 Spring Clinical Meetings

> “NKF 2026 Spring Clinical Meetings Abstracts”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Phase 1, open-label, single-dose design

> “A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Severe Renal Impairment and Healthy Subjects With Normal Renal Function”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.3-2"></a>

#### Design details in the registry record

| Field | Registry entry |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.3-3"></a>

#### Comparison with matched healthy participants

> “We compared systemic exposures of IXP to matched healthy participants using geometric least squares mean ratios (GLSMR).”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Severe renal impairment not on dialysis

> “severe renal impairment (estimated glomerular filtration rate of <30 mL/min and not on dialysis)”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.4-2"></a>

#### Key criteria in the registry record

> “Body mass index (BMI) of 18.5 to 40.0 kilogram per meter square (kg/m^2)”
> “Stable renal function for at least 1 month prior to enrollment”
> “Uncontrolled hypertension”
> “Any condition possibly affecting drug absorption”
> “Other protocol defined Inclusion/Exclusion criteria may apply.”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.4-3"></a>

#### Age range and healthy volunteers

| Field | Registry entry |
| --- | --- |
| Ages eligible | “18 Years to 80 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Single 45 mg oral dose

> “evaluated the PK and safety of IXP following a single 45-mg oral dose”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.5-2"></a>

#### Arms in the registry record

> “Experimental: Cohort 1: Severe Renal Impairment”
> “Experimental: Cohort 1: Healthy Participants”
> “Participants will receive a single dose of IXP on Day 1.”
> “Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Plasma Cmax and AUC0-inf as the Primary Endpoints

<a id="topic-3.1.6.6.1-1"></a>

##### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum Observed Plasma Concentration (Cmax) of IXP” | “Day 1 up to Day 7” |
| Primary | “Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of IXP” | “Day 1 up to Day 7” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “Day 1 through completion of study participation (up to a maximum of 17 days)” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.6.1-2"></a>

##### Elimination pathways of inaxaplin

> “IXP primarily undergoes hepatic metabolism, while renal clearance represents a minor pathway.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.6.1-3"></a>

##### Renal clearance in the healthy-adult studies

> “Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “16” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.7.1-2"></a>

##### Enrollment reported in the congress abstract

> “Sixteen participants were enrolled in the renal study”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Exposure in severe renal impairment compared with healthy matches

> “There were no clinically meaningful differences observed in IXP exposures in participants with severe renal impairment (N=8) compared to their healthy matches (N=8; GLSMR <120%).”
> “No clinically meaningful differences in IXP PK were observed in patients with renal impairment or with mild to moderate hepatic impairment up to and including a CP score of 7. Therefore, no dose adjustment of IXP is anticipated in these populations.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Safety in the renal and hepatic impairment studies

> “IXP was generally safe and well tolerated in both studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary: study limitations

VX19-147-007 gave a single 45 mg dose to 16 participants: 8 with severe renal impairment (estimated glomerular filtration rate below 30 mL/min and not on dialysis) and 8 matched healthy participants. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<120%” without point estimates or confidence intervals and reports safety only as “generally safe and well tolerated”. The ClinicalTrials.gov record lists no posted results. Participants on dialysis and multiple-dose exposure were not studied, and five of the six abstract authors list a Vertex Pharmaceuticals affiliation.

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171); [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.9-2"></a>

#### Author affiliations of the congress abstract

> “Chelsea Hosey1, Vasco Oliveira1, Danieli Salinas1, Liz Minevich1, Glenn Chertow2, Swarupa Kulkarni1.”
> “1Vertex Pharmaceuticals Inc; 2Stanford University School of Medicine”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.9-3"></a>

#### No results posted in the registry record

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
